Intec Pharma Ltd

Intec Pharma — Technical Presentation (July 2019)

9 slides from Intec Pharma's technical presentation, Jul 22, 2019

  1. Slide 1: Phase 3 ACCORDANCE Study Top-Line Results July 22, 2019

    Phase 3 ACCORDANCE Study Top - Line Results July 22 , 2019

  2. Slide 2: Forward-looking statements

    This presentation by Intec Pharma Ltd. (referred to as “we” or “our”) may contain forward - looking statements about our expectations, beliefs and intentions regarding, among other things, our product development efforts, business, financial condition, results of operation s, strategies, plans and pr

  3. Slide 3: Parkinson's Disease and Levodopa

    • Parkinson ’ s disease (PD ) results from a continuing loss of dopamine - producing nerve cells. • Dopamine is required for normal functioning of the central nervous system. • Levodopa is generally considered to be the most effective and widely used treatment for Parkinson ’ s disease. • Up to 50 %

  4. Slide 4: The Accordion Pill: A new platform for oral drug delivery

    The Accordion Pill: A new platform for oral drug delivery AP capsule dissolves and outer layers facilitate unfolding mechanism of films Layers comprise an inner, controlled release drug - containing layer, and immediate release layer(s) for multiple drug release profiles and/or fixed - dose combinat

  5. Slide 5: AP-CD/LD Phase III Trial Design

    AP - CD/LD Phase III Trial Design ~ 9 0+ Clinical sites across 10 countries 6 Weeks 13 Weeks 2 Weeks 50 / 400 , 50 / 500 BID, TID Open label N= 462 Double Blind 12 Months 6 Weeks Optimization on Sinemet® AP - CD/LD Conversion Enrollment Committee Review Treatment Period Sinemet + AP - CD/LD dummy Tr

  6. Slide 6: Primary Analysis - Average Hours of OFF Time Daily

    Primary Analysis - Average Hours of “ OFF ” Time Daily

  7. Slide 7: Preliminary Post Ad Hoc Analysis - Patients Not Requiring Maximal AP Dose

    Preliminary Post Ad Hoc Analysis - All Patients NOT Requiring The Maximal AP Dose of 1500 mg LD

  8. Slide 8: Preliminary Post Ad Hoc Analysis - Patients Who Received 1.6 to 2.0 Dose Ratio

    Preliminary Post Ad Hoc Analysis - Patients Who Received 1.6 to 2.0 Dose Ratio of AP LD to IR LD

  9. Slide 9: Thank you www.intecpharma.com

    Thank you www.intecpharma.com

Intec Pharma — Technical Presentation (July 2019) on 6ix